yvandenbroek
/
sprookjes
/
Login
Register
TriplyDB
sprookjes
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
2
Q33418257-B02E3430-6550-4028-A67E-52AB456393BE
Q33418257-B02E3430-6550-4028-A67E-52AB456393BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33418257-B02E3430-6550-4028-A67E-52AB456393BE
Phase 1 dose-escalation study of IV ixazomib, an investigational proteasome inhibitor, in patients with relapsed/refractory lymphoma.
P2860
Q33418257-B02E3430-6550-4028-A67E-52AB456393BE
BestRank
Statement
http://www.wikidata.org/entity/statement/Q33418257-B02E3430-6550-4028-A67E-52AB456393BE
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
397ca62ed3ceb3ade33ab57d07cdef7780142570
P2860
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients